KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
Go back to KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)| Merck & Co. (NYSE: MRK) | Delayed: 147.15 +2.24 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.91 | 52 Week High | $65.46 | |||
| Open | $145.74 | 52 Week Low | $47.97 | |||
| Day High | $147.65 | P/E | 100.10 | |||
| Day Low | $145.32 | EPS | $1.47 | |||
| Volume | 11,063,719 | |||||
